In a number of countries, like the UK and Canada, a marijuana plant-derived oral extract drug, Sativex, is approved for the treatment of MS-related spasticity, which in turn is reducing the need for prescription meds. Although it is still not approved in the United States, this finding is consistent with a U.S. study that found that increased medical and recreational storefront dispensary counts are associated with reduced opioid related mortality rates during the study period. Check out the full article here!
Your Grow Pro,
Rachele S.
